ZA200804488B - Pyrimidine derivatives for the treatment of abnormal cell growth - Google Patents

Pyrimidine derivatives for the treatment of abnormal cell growth

Info

Publication number
ZA200804488B
ZA200804488B ZA200804488A ZA200804488A ZA200804488B ZA 200804488 B ZA200804488 B ZA 200804488B ZA 200804488 A ZA200804488 A ZA 200804488A ZA 200804488 A ZA200804488 A ZA 200804488A ZA 200804488 B ZA200804488 B ZA 200804488B
Authority
ZA
South Africa
Prior art keywords
treatment
cell growth
abnormal cell
pyrimidine derivatives
pyrimidine
Prior art date
Application number
ZA200804488A
Other languages
English (en)
Inventor
Arcari Joel Thomas
Bhattacharya Samit Kumar
Brosius Arthur Douglas
Luzzio Michael Joseph
Nelson Kendra Louise
Pan Gonghua
Southers James Alfred
Wishka Donn Gregory
Xiao Jun
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ZA200804488B publication Critical patent/ZA200804488B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
ZA200804488A 2005-12-21 2008-05-23 Pyrimidine derivatives for the treatment of abnormal cell growth ZA200804488B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75270805P 2005-12-21 2005-12-21

Publications (1)

Publication Number Publication Date
ZA200804488B true ZA200804488B (en) 2009-05-27

Family

ID=38038639

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200804488A ZA200804488B (en) 2005-12-21 2008-05-23 Pyrimidine derivatives for the treatment of abnormal cell growth

Country Status (30)

Country Link
US (1) US7820648B2 (ru)
EP (1) EP1966207A2 (ru)
JP (1) JP4332590B2 (ru)
KR (1) KR101060051B1 (ru)
CN (1) CN101346380B (ru)
AP (1) AP2008004488A0 (ru)
AR (1) AR058399A1 (ru)
AU (1) AU2006327871A1 (ru)
BR (1) BRPI0620324A2 (ru)
CA (1) CA2634646C (ru)
CR (1) CR10095A (ru)
DO (1) DOP2006000289A (ru)
EA (1) EA014551B1 (ru)
EC (1) ECSP088563A (ru)
GT (1) GT200600517A (ru)
HN (1) HN2006042221A (ru)
IL (1) IL191555A0 (ru)
MA (1) MA30075B1 (ru)
ME (1) MEP0908A (ru)
NL (1) NL2000375C2 (ru)
NO (1) NO20082338L (ru)
PE (1) PE20071138A1 (ru)
RS (1) RS20080272A (ru)
SV (1) SV2008002969A (ru)
TN (1) TNSN08270A1 (ru)
TW (1) TW200736258A (ru)
UA (1) UA89123C2 (ru)
UY (1) UY30051A1 (ru)
WO (1) WO2007072158A2 (ru)
ZA (1) ZA200804488B (ru)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0413018B8 (pt) 2003-07-30 2021-05-25 Rigel Pharmaceuticals Inc composto, e, uso de um composto
US20070032514A1 (en) * 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
EP2041132A2 (en) * 2006-07-06 2009-04-01 Boehringer Ingelheim International GmbH New compounds
WO2008051547A1 (en) 2006-10-23 2008-05-02 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors
EA016679B1 (ru) 2007-04-18 2012-06-29 Пфайзер Продактс Инк. Сульфониламидные производные для лечения аномального роста клеток
BRPI0814432A2 (pt) * 2007-07-17 2017-05-09 Rigel Pharmaceuticals Inc pirimidinadiaminas substituídas por amina cíclica como inibidores de pkc
EP2231620A1 (en) * 2007-12-03 2010-09-29 Boehringer Ingelheim International GmbH Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
JP2011515372A (ja) * 2008-03-20 2011-05-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換ピリミジン類の位置選択的製造法
UY31714A (es) * 2008-03-20 2009-11-10 Boehringer Ingelheim Int Preparación selectiva de pirimidinas sustituidas
ES2472323T3 (es) 2008-06-17 2014-06-30 Astrazeneca Ab Compuestos de piridina
EP2161259A1 (de) 2008-09-03 2010-03-10 Bayer CropScience AG 4-Halogenalkylsubstituierte Diaminopyrimidine als Fungizide
US20110071158A1 (en) * 2009-03-18 2011-03-24 Boehringer Ingelheim International Gmbh New compounds
TW201100441A (en) * 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
US8729265B2 (en) 2009-08-14 2014-05-20 Boehringer Ingelheim International Gmbh Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US8466155B2 (en) 2009-10-02 2013-06-18 Boehringer Ingelheim International Gmbh Pyrimidines
TWI513694B (zh) 2010-05-11 2015-12-21 Amgen Inc 抑制間變性淋巴瘤激酶的嘧啶化合物
EP2571867B1 (en) 2010-05-21 2015-11-04 Noviga Research AB Novel pyrimidine derivatives
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
PL2646448T3 (pl) 2010-11-29 2017-12-29 OSI Pharmaceuticals, LLC Makrocykliczne inhibitory kinazy
EP2688883B1 (en) 2011-03-24 2016-05-18 Noviga Research AB Pyrimidine derivatives
WO2013083206A1 (en) 2011-12-09 2013-06-13 Chiesi Farmaceutici S.P.A. Derivatives of 4-hydroxy-1,2,3,4-tetrahydronaphtalen-1-yl urea and their use in the treatment of, inter alia, diseases of the respiratory tract
KR20140114344A (ko) 2011-12-23 2014-09-26 셀좀 리미티드 키나제 억제제로서의 피리미딘-2,4-디아민 유도체
CN103655577A (zh) * 2012-09-20 2014-03-26 杨育新 一类治疗创伤性脑损伤疾病的化合物及其用途
CN103664957A (zh) * 2012-09-25 2014-03-26 杨子娇 一类治疗房角狭窄的化合物及其用途
CN105130907B (zh) * 2015-07-29 2018-10-16 沈阳药科大学 嘧啶类化合物及其用途
EP3484528B1 (en) 2016-07-18 2020-11-25 Janssen Pharmaceutica NV Tau pet imaging ligands
WO2020023851A1 (en) * 2018-07-26 2020-01-30 Yale University Bifunctional substitued pyrimidines as modulators of fak proteolyse
JP2024502174A (ja) * 2021-01-07 2024-01-17 オンタリオ・インスティテュート・フォー・キャンサー・リサーチ（オーアイシーアール） Ｎｕａｋキナーゼの阻害剤としてのチエニル及びシクロアルキルアミノピリミジン化合物、その組成物及び使用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB0004887D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
WO2003095448A1 (en) 2002-05-06 2003-11-20 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
WO2004048343A1 (en) * 2002-11-28 2004-06-10 Schering Aktiengesellschaft Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
WO2004067516A1 (en) * 2003-01-30 2004-08-12 Boehringer Ingelheim Pharmaceuticals, Inc. 2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta
EA200601796A1 (ru) * 2004-05-14 2007-04-27 Пфайзер Продактс, Инк. Пиримидиновые производные для лечения аномального клеточного роста
WO2005111016A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth

Also Published As

Publication number Publication date
EA200801287A1 (ru) 2008-10-30
AP2008004488A0 (en) 2008-06-30
RS20080272A (en) 2009-07-15
AR058399A1 (es) 2008-01-30
BRPI0620324A2 (pt) 2011-11-08
UY30051A1 (es) 2007-07-31
US7820648B2 (en) 2010-10-26
JP4332590B2 (ja) 2009-09-16
SV2008002969A (es) 2010-08-17
WO2007072158A8 (en) 2008-08-14
TW200736258A (en) 2007-10-01
UA89123C2 (ru) 2009-12-25
GT200600517A (es) 2007-09-13
WO2007072158A2 (en) 2007-06-28
TNSN08270A1 (fr) 2009-10-30
CN101346380A (zh) 2009-01-14
CA2634646A1 (en) 2007-06-28
PE20071138A1 (es) 2007-12-29
WO2007072158A3 (en) 2007-12-27
US20080234303A1 (en) 2008-09-25
EA014551B1 (ru) 2010-12-30
NL2000375A1 (nl) 2007-06-25
MEP0908A (xx) 2010-02-10
EP1966207A2 (en) 2008-09-10
JP2009520807A (ja) 2009-05-28
NO20082338L (no) 2008-06-25
HN2006042221A (es) 2010-01-18
NL2000375C2 (nl) 2008-01-03
CA2634646C (en) 2012-04-10
CR10095A (es) 2008-07-17
KR20080077026A (ko) 2008-08-20
KR101060051B1 (ko) 2011-08-29
AU2006327871A1 (en) 2007-06-28
MA30075B1 (fr) 2008-12-01
DOP2006000289A (es) 2007-07-31
CN101346380B (zh) 2012-02-29
ECSP088563A (es) 2008-07-30
IL191555A0 (en) 2008-12-29

Similar Documents

Publication Publication Date Title
IL191555A0 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
AP2006003790A0 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
TWI369205B (en) Sulfonyl amide derivatives for the treatment of abnormal cell growth
IL172047A0 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
AU2003288603A8 (en) Pyrimidine derivates for the treatment of abnormal cell growth
HK1126121A1 (en) Method of treating abnormal cell growth
IL190135A (en) A process for preparing pyrimidindione derivatives
HK1142591A1 (en) Amide derivative for inhibiting the growth of cancer cells
PT1966162T (pt) Derivados de pirimidina
ZA200704918B (en) Methods for the production of ansamitocins
EG25081A (en) Use of prolines for improving growth and/or yield.
ZA200708591B (en) Pyrimidine derivatives for treatment of hyperproliferative disorders
PL1959957T3 (pl) Pochodne pirymidyloaminobenzamidu do leczenia neurowłókniakowatości
ZA200804777B (en) Method of treating abnormal cell growth
IL213474A0 (en) Processes for the preparation of cyclopropyl-amide derivatives
PL377686A1 (pl) Pochodne 4-anilinochinazoliny do leczenia anormalnego wzrostu komórek
ZA200803526B (en) Process for stabilization of bacterial cells
GB0516085D0 (en) Treatment of viable cells